Drugs / Vabametkib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05541822 | Jan 2023 → Feb 2029 expected | cancer | Abion Inc | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vabametkib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05541822 ↗ |
| Action | Inhibit | “selective MET TKI vabametkib” PMID 41927036 ↗ Mar 2026 |
| Modality | Small molecule | “selective MET TKI vabametkib” PMID 41927036 ↗ Mar 2026 |
| Route | Oral | “Route of Administration: Oral” NCT05541822 ↗ |
| Target | MET | “selective MET TKI vabametkib” PMID 41927036 ↗ Mar 2026 |